Skip to main content Skip to section navigation Skip to footer
Avalo Therapeutics, Inc. Corporate Home
  • About
    • Overview
    • Leadership
    • Board of directors
    • Register for updates
    • Contact
  • Science
    • Overview
    • IL-1β in HS
    • IL-1β in CPPD
  • Pipeline
    • Overview
    • AVTX-009 for HS
    • AVTX-009 for CPPD
  • Patients
    • Our commitment
    • Clinical trials
    • Resources
    • Access to investigational therapies
  • Investors
    • Overview
    • News, events & presentations
    • Analyst coverage
    • Stock data
    • SEC filings
    • Corporate governance
    • IR resources
  • Careers
    • Overview
    • Values
    • Benefits
    • Job openings

Press Releases

News, events & presentations

News, events & presentations

  • Press Releases
  • Events
  • Presentations
  • Email alerts
Oct 18, 2017 8:15 am EDT
Cerecor, Inc. Regains Compliance with NASDAQ Minimum Bid Price Requirement
Aug 14, 2017 8:04 am EDT
Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer
Aug 14, 2017 8:02 am EDT
Cerecor Inc. Reports Second Quarter 2017 Financial Results
Aug 14, 2017 8:00 am EDT
Cerecor Announces Divestiture of CERC-501 to Janssen Pharmaceuticals, Inc.
May 30, 2017 8:30 am EDT
Cerecor to present at the American Society for Clinical Psychopharmacology Conference
May 15, 2017 8:30 am EDT
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
May 9, 2017 8:30 am EDT
Cerecor Inc. Reports First Quarter 2017 Financial Results
May 1, 2017 8:30 am EDT
Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept Trial of CERC-501 in Treatment-Resistant Depression
Apr 28, 2017 8:30 am EDT
Cerecor Inc. Closes $5.0 Million Private Placement
Mar 14, 2017 9:37 am EDT
Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Next Pagearrow_forward
  • Contact IR
  • RSS
  • Email Alerts
  • Accessibility
    accessibility
610.254.4205
in
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Avalo
PRIVACY POLICY DISCLAIMER
©2026 Avalo Therapeutics, Inc.